Please check your internet connection and try again.
# Ecospirin (Aspirin, Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and antiplatelet properties. The enteric coating is designed to delay absorption and reduce gastric irritation.
## Primary Indications
* **Antiplatelet therapy:** Prevention of myocardial infarction, stroke, and cardiovascular death in patients with established cardiovascular disease or at high risk.
* **Analgesia and antipyresis:** Relief of mild to moderate pain and fever.
* **Inflammation:** Adjunctive therapy for inflammatory conditions (less common due to availability of other NSAIDs).
## Adult Dosing
* **Antiplatelet prophylaxis:** Typically 75 mg to 100 mg once daily. Higher doses of 150-325 mg may be used initially in specific acute cardiovascular scenarios, then reduced to maintenance dose.
* **Analgesia/Antipyresis:** 325 mg to 650 mg every 4 to 6 hours as needed. Maximum daily dose generally not to exceed 4000 mg.
* **Rheumatic fever prophylaxis:** 50 mg/kg/day divided every 4-6 hours.
*Note: Dosing for cardiovascular prevention is often guided by local protocols and patient-specific risk factors. The specific dose of Ecospirin available may dictate the formulation used.*
## Pediatric Dosing
* **Analgesia/Antipyresis:** 10 mg/kg/dose to 15 mg/kg/dose every 4 to 6 hours. Maximum daily dose generally not to exceed 4000 mg.
* **Kawasaki Disease:** Doses vary widely, often starting with a higher dose (e.g., 80-100 mg/kg/day divided qid) followed by a low dose (e.g., 3-5 mg/kg/day once daily) for extended periods. Consult specific guidelines.
* **Rheumatic Fever Prophylaxis:** 50 mg/kg/day divided every 4-6 hours.
**Important:** Aspirin should generally be avoided in children and adolescents with viral infections (e.g., influenza, varicella) due to the risk of Reye's syndrome.
## Dose Adjustments
No specific dose adjustments are typically required for hepatic or renal impairment, but caution is advised, especially in severe disease, due to potential for adverse effects.
## Contraindications
* Known hypersensitivity to aspirin, salicylates, or NSAIDs.
* Asthma, urticaria, or allergic-type reactions precipitated by aspirin or other NSAIDs.
* Active peptic ulceration or gastrointestinal bleeding.
* Children and adolescents with viral infections (risk of Reye's syndrome).
* Third trimester of pregnancy.
* Severe hepatic or renal impairment.
* Hemophilia and other bleeding diatheses.
## Adverse Effects
* **Gastrointestinal:** Dyspepsia, heartburn, nausea, vomiting, abdominal pain, occult bleeding, frank GI bleeding, ulceration.
* **Hematologic:** Increased bleeding time, bruising, epistaxis, menorrhagia.
* **Hypersensitivity:** Bronchospasm, urticaria, angioedema, anaphylaxis.
* **Renal:** Renal insufficiency, papillary necrosis (with chronic high-dose use).
* **Auditory:** Tinnitus, hearing loss (especially with high doses).
* **Reye's Syndrome:** In children and adolescents with viral infections.
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs and COX-2 inhibitors:** Increased risk of GI toxicity and bleeding.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Antihypertensives (e.g., ACE inhibitors, ARBs, diuretics):** May decrease antihypertensive efficacy and increase risk of renal impairment.
* **Methotrexate:** Increased methotrexate toxicity.
* **Uricosuric agents (e.g., probenecid):** Decreased uricosuric effect.
* **Alcohol:** Increased risk of GI bleeding.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding (e.g., bruising, hematuria, melena, epistaxis).
* **GI symptoms:** Assess for dyspepsia, abdominal pain, or signs of GI distress.
* **Renal function:** Consider monitoring in patients with risk factors for renal impairment or on long-term therapy.
* **Tinnitus/Hearing:** Advise patients to report tinnitus or hearing changes.
## Clinical Pearls
* The enteric coating reduces gastric irritation but does not eliminate the risk of GI bleeding, especially with long-term use or higher doses. Do not crush or chew enteric-coated tablets.
* Aspirin should be discontinued at least 5-7 days before elective surgery.
* Consider concurrent gastroprotection (e.g., proton pump inhibitor) for patients at high risk of GI bleeding.
* In acute cardiovascular events (e.g., suspected MI), chewable aspirin (non-enteric coated) is preferred for faster absorption.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for definitive guidance. Dosing and recommendations may vary based on patient-specific factors and local protocols.*
